Retatrutide price per month: why there is none yet
Prices in US dollars at the verification date. Ranges are published list or program prices where a primary source exists; notes say when a figure is a typical market range instead.
| Channel | Price (USD) | Notes |
|---|---|---|
| With insurance | Not published | Not covered. Medicare Part D and commercial pharmacy benefits cover FDA approved drugs for accepted indications, and retatrutide is not approved. Participants in registered clinical trials typically receive the study drug at no cost; ClinicalTrials.gov lists recruiting retatrutide trials. [2] [10] |
| Branded, from a pharmacy | Not published | No list price. Retatrutide is an investigational drug that is not approved by FDA or any other regulator, so no pharmacy can dispense it and the manufacturer has published no price. Phase 3 trials (TRIUMPH for obesity) are the confirmatory step; any price would be set only after approval. For context only, approved GLP-1 medicines had these prices at their manufacturers' pricing pages, checked 2026-09-22: semaglutide list prices of $1,027.51 to $1,349.02 per month and self-pay prices of $149 to $499 per month, and tirzepatide list prices of $499 to $1,112.16 per month and self-pay prices of $299 to $699 per month. These are different drugs, not a retatrutide price. [1] [5] [6] [7] [8] [9] |
| Compounded pharmacy | Not published | No lawful compounded price. Retatrutide is not a component of an approved drug and is not on the 503A bulks list, so neither 503A pharmacies nor 503B outsourcing facilities can lawfully compound it. FDA has warned that unapproved GLP-1 class products sold online are not evaluated for safety, quality, or dose. Products sold as retatrutide or as research chemicals are not lawful for human use and are not a comparable price. [3] [4] |
What is the list price of retatrutide?
There is no list price: retatrutide is not an FDA approved drug, and the only lawful access is a registered clinical trial. Approved GLP-1 medicines, which are the lawful options today, had manufacturer list prices of roughly $499 to $1,349 per month and self-pay prices of $149 to $699 per month at the verification date. Products sold as retatrutide online are not lawful for human use and are not a comparable price.
Does insurance cover retatrutide?
Not covered by commercial plans or Medicare because it is an unapproved investigational drug. Clinical trial participants typically receive it at no cost.
What changes the price?
- No price until FDA approval; any list price would be set by the manufacturer after approval
- No lawful compounding basis while it is investigational and not a component of an approved drug
- Clinical trial enrollment is the only lawful access today
Frequently asked questions
How much does retatrutide cost without insurance?
No list price. Retatrutide is an investigational drug that is not approved by FDA or any other regulator, so no pharmacy can dispense it and the manufacturer has published no price. Phase 3 trials (TRIUMPH for obesity) are the confirmatory step; any price would be set only after approval. For context only, approved GLP-1 medicines had these prices at their manufacturers' pricing pages, checked 2026-09-22: semaglutide list prices of $1,027.51 to $1,349.02 per month and self-pay prices of $149 to $499 per month, and tirzepatide list prices of $499 to $1,112.16 per month and self-pay prices of $299 to $699 per month. These are different drugs, not a retatrutide price. [1] [5] [6] [7] [8] [9]
Does insurance cover retatrutide?
Not covered by commercial plans or Medicare because it is an unapproved investigational drug. Clinical trial participants typically receive it at no cost. [2] [10]
What is the list price of retatrutide?
There is no list price: retatrutide is not an FDA approved drug, and the only lawful access is a registered clinical trial. Approved GLP-1 medicines, which are the lawful options today, had manufacturer list prices of roughly $499 to $1,349 per month and self-pay prices of $149 to $699 per month at the verification date. Products sold as retatrutide online are not lawful for human use and are not a comparable price. [1] [5] [6] [7] [8] [9]
Related pages
- Retatrutide: evidence, legality, and access
- Dulaglutide vs retatrutide (Dulaglutide cost)
- Retatrutide vs mazdutide
- Retatrutide vs survodutide
- Semaglutide vs retatrutide (Semaglutide cost)
- Tesamorelin vs retatrutide (Tesamorelin cost)
- Tirzepatide vs retatrutide (Tirzepatide cost)
- Obesity and chronic weight management: peptide evidence
- Obstructive sleep apnea: peptide evidence
- Osteoarthritis: peptide evidence
- Where it is legal to get: peptide law by state
- Full cost index
From the blog
- How to get retatrutide: clinical trials, expanded access, and the law
Retatrutide is not approved, so a clinical trial is the only lawful way to get it. How to search ClinicalTrials.gov, how expanded access works, and why online and compounded sources are unlawful.
- Retatrutide before and after: weight loss by dose and week in the trials
What retatrutide trials measured: 24.2% mean weight loss at 48 weeks in phase 2, up to 28.3% at 80 weeks in phase 3, and what happened to fat, waist size, and blood sugar.
- Retatrutide benefits beyond weight loss: liver fat, blood sugar, and blood pressure
What retatrutide trials measured besides weight: liver fat, HbA1c, blood pressure, lipids, fat mass, and knee pain. What is proven, what is post hoc, and what is still unknown.
- Retatrutide side effects: what the trials reported, dose by dose
Nausea, diarrhea, dysesthesia, heart rate, and dropouts in the retatrutide trials, with placebo rates. What the data say about safety, and what is still unknown.
- Retatrutide: where the phase 3 program stands
Five phase 3 readouts, one peer-reviewed paper, and no approval yet. What the retatrutide trials have shown, what is still pending, and why no one can lawfully sell it today.
- Peptides for weight loss, ranked by human evidence
Tirzepatide, semaglutide, and liraglutide lead on human trials. Retatrutide is trial-only, and AOD-9604 and 5-amino-1MQ are animal-only. Ranking, legal status, and dated prices.
Sources
- [1]Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab 2026PubMed 41090431, 2026
- [2]ClinicalTrials.gov: registered clinical trials of retatrutide (LY3437943)
- [3]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA
- [4]FDA: concerns with unapproved GLP-1 drugs used for weight lossFDA
- [5]Manufacturer list price (wholesale acquisition cost) page for semaglutide for weight management, pens and tablets, accessed 2026-09-22
- [6]Manufacturer list price (wholesale acquisition cost) page for semaglutide injection and tablets for type 2 diabetes, accessed 2026-09-22
- [7]Manufacturer direct-to-patient pharmacy page with semaglutide self-pay and commercial savings prices, accessed 2026-09-22
- [8]Manufacturer pricing information page for tirzepatide for weight management: list price, self-pay prices by dose, and commercial savings card, accessed 2026-09-22
- [9]Manufacturer pricing information page for tirzepatide for type 2 diabetes: list price and savings card eligibility, accessed 2026-09-22
- [10]Medicare.gov: prescription drug coverage (Part D and outpatient drugs)